On Thursday, Novartis announced its intent to separate its generics and biosimilars division, Sandoz, into a new publicly traded standalone company by way of a...
Biocon has entered into a global partnership with Sandoz, a division of Swiss pharmaceutical Novartis. As per the terms of agreement, both companies will develop,...